Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Fig. 5

Flow cytometry of immune cells in peripheral blood of mice demonstrated a successful immune reconstitution. A Gating strategy of lymphocytes including T cells and B cells. Total leukocytes were gated with CD45+, in total lymphocytes were gated with CD3+. Then the CD4+ helper T cells, CD8+ cytotoxic T cells, and CD19+ B cells were then delineated in CD3+ lymphocytes, respectively. Next, CD4+ T cells were further divided into early activation (CD69+), middle activation (CD25+), late activation (HLA-DR+); exhausted (PD1+/CTLA-4+/TIM3+/TIGIT+), as well as immunosuppressive Treg (FOXP3+CD25+) T cells. Similarly, we also applied the above gating strategy in CD8+T cells. In addition, we checked IFN-γ and Granzyme B, which were related to killing functions. B Gating strategy of myeloid cells involving macrophages and MDSCs. Among CD45+ leukocytes, overall myeloid lineage cells were delineated with CD11b+. Total macrophages were gated with CD68+; classically activated M1 macrophages were gated with CD86+; conditionally activated M2 macrophages were gated with CD206+; and immunosuppressive MDSCs were circled with HLA-DR-CD33+. C Comparison of the proportion of major cell components of tumor-infiltrating immune cells in each treatment group

Back to article page